AOBiome Stock
Life Sciences Company
Sign up today and learn more about AOBiome Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About AOBiome Stock
AOBiome is a life sciences company that focuses on transforming human health by developing microbiome-based therapies for inflammatory conditions. The company's portfolio includes multiple clinical-stage programs; a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2a study to treat patients with adult eczema (atopic dermatitis), a Phase 2 study for the prevention of episodic migraines, and a Phase 1b/2a clinical trial for the treatment of allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. Its product candidates harness a single strain of class-defining, auto-regulating Ammonia Oxidizing Bacteria (AOB), a human commensal, enabling healthcare practitioners to produce well-understood and well-characterized biochemical compound that are critical to human health. AOBiome was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Investors
iCarbonX
Wakestream Ventures
Funding History
March 2013 | $630K |
---|---|
August 2014 | $577K |
December 2014 | $7.5M |
January 2017 | $30.0M |
Management
Chief Executive Officer
Todd Krueger
Press
downtoearth - Dec, 20 2023
Microbiome-based skincare technology holds unique benefits ...kompasjatim - Dec, 20 2023
Outlook Pasar Modulator microbiome kulit 2024-2031 ...openpr - Dec, 20 2023
Microbiome Therapeutics Market Industry Outlook, Size, Growth Factors and Forecast 2029openpr - Dec, 20 2023
Microbiome in Skincare Marke Current Scenario with Future Aspect Analysis